story of the week
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The New England Journal of Medicine
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
N. Engl. J. Med 2019 Dec 11;[EPub Ahead of Print], RK Murthy, S Loi, A Okines, E Paplomata, E Hamilton, SA Hurvitz, NU Lin, V Borges, V Abramson, C Anders, PL Bedard, M Oliveira, E Jakobsen, T Bachelot, SS Shachar, V Müller, S Braga, FP Duhoux, R Greil, D Cameron, LA Carey, G Curigliano, K Gelmon, G Hortobagyi, I Krop, S Loibl, M Pegram, D Slamon, MC Palanca-Wessels, L Walker, W Feng, EP WinerFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.